Advertisement

Featured in NEJM Journal Watch: Infliximab or Adalimumab in Crohn Disease? — Physician’s First Watch

Medical News |
April 29, 2014

Featured in NEJM Journal Watch: Infliximab or Adalimumab in Crohn Disease?

By the NEJM Journal Watch Editors

In a retrospective cohort study of U.S. Medicare patients, rates of persistent drug use at week 26, surgery, and hospitalization were similar with either agent. The study, which appears in Clinical Gastroenterology and Hepatology, examined data from some 2300 new users of the drugs between 2006 and 2010.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement